The posterior superior iliac spine (PSIS) is the gold-standard bone marrow biopsy site in over 90% of cases — and for good reason. It offers a large, accessible area of hematopoietically active marrow with a complication rate below 0.1%. But site selection is only one piece of a procedure that has evolved significantly in recent years, from powered biopsy devices to CT-guided approaches for complex patients.
Whether you’re a trainee preparing for your first supervised biopsy, a seasoned hematologist evaluating newer techniques, or a patient trying to understand what’s about to happen to you, this guide covers the anatomy, site-selection rationale, procedural advances, and practical pearls that actually matter in clinical practice.
Why the Posterior Iliac Crest Is the Preferred Biopsy Site
The posterior superior iliac spine sits at the top of the pelvis, just below those two dimples on your lower back. It’s the default site because it checks every box: thick cortical bone that anchors the needle, abundant marrow space, safe distance from major neurovascular structures, and a patient position (prone or lateral decubitus) that’s comfortable enough for most people.
The marrow harvested here is representative of overall hematopoietic activity in adults. Studies consistently show adequate specimen length (the target is ≥1.5 cm of intact core) is achieved more reliably at the PSIS than at any alternative site.
Alternative Biopsy Sites: When and Why
Sometimes the posterior iliac crest isn’t an option. Prior radiation, surgical hardware, severe obesity, infection overlying the site, or a patient who simply cannot be positioned prone — all of these force clinicians to look elsewhere.
| Biopsy Site | Primary Indication | Key Advantage | Key Risk/Limitation |
|---|---|---|---|
| Posterior superior iliac spine | Default for nearly all patients | Highest yield, lowest complication rate (<0.1%) | Difficult in morbid obesity |
| Anterior iliac crest | Patients who cannot lie prone | Supine positioning possible | Thinner cortex, slightly lower specimen quality |
| Sternum (aspiration only) | Aspiration when iliac sites unavailable | Easily accessible, thin cortex for aspiration | Risk of mediastinal penetration — never used for trephine biopsy |
| Tibia | Infants <1 year old | Proximal tibia is highly cellular in neonates | Not useful in adults (fatty marrow conversion) |
| Vertebral body (CT-guided) | Focal lesions seen on imaging | Targets specific pathology | Requires interventional radiology, higher cost |
A critical safety point: sternal biopsy (trephine core) is essentially contraindicated in adults. The sternum is only 1 cm thick in many patients, and needle advancement beyond the posterior cortex can puncture the heart or great vessels. Sternal aspiration is occasionally performed, but only by experienced operators using depth-limited needles.
7 Techniques and Advances Changing Bone Marrow Biopsy
1. Powered (Battery-Driven) Biopsy Devices
Devices like the OnControl system use a battery-powered drill to penetrate cortical bone. Randomized trials show they reduce procedure time by roughly 50% and consistently yield longer, less-crushed core specimens compared to manual Jamshidi needles. Many patients report less pain with powered devices, likely because the rapid penetration minimizes the sustained pressure on periosteum.
2. Adequate Specimen Length Standards
The International Council for Standardization in Haematology (ICSH) recommends a trephine core of at least 1.5 cm after processing (which causes ~20% shrinkage, so aim for ≥2 cm at the bedside). Specimens below this threshold risk false-negative results, particularly for focal diseases like lymphoma staging.
3. Touch Preparations (Imprints)
Rolling the fresh core biopsy across glass slides creates touch preps — an often-underutilized technique that provides cytologic detail complementary to the histologic sections. They’re especially valuable when the aspirate is a “dry tap” (failed aspiration due to fibrosis or packed marrow).
4. CT-Guided and Image-Guided Biopsies
For focal bone lesions or patients with distorted anatomy, CT-guided biopsy allows precise needle placement into a specific lesion. This approach has a diagnostic yield exceeding 90% for targeted lesions, compared with ~75% for blind biopsies of focal disease.
5. Conscious Sedation Protocols
While local anesthesia with 1% lidocaine (infiltrated down to and including the periosteum) remains standard, many centers now offer light conscious sedation with midazolam and fentanyl for anxious patients. Pediatric patients generally undergo the procedure under general anesthesia or deep sedation.
6. Flow Cytometry Integration
Modern protocols routinely send aspirate samples for multiparameter flow cytometry, which can immunophenotype thousands of cells in minutes. This has become indispensable for diagnosing and classifying leukemias, lymphomas, and myelodysplastic syndromes with sensitivity down to detecting 1 abnormal cell per 10,000.
7. Next-Generation Sequencing (NGS) on Marrow Samples
Molecular profiling of bone marrow aspirate is increasingly standard. Targeted NGS panels can identify mutations in genes like FLT3, NPM1, IDH1/2, and TP53 — information that directly drives treatment decisions in acute myeloid leukemia and MDS. Some institutions now reflexively send marrow for a 40–80 gene myeloid panel at the time of initial biopsy.
Complication Rates: What the Data Actually Shows
Bone marrow biopsy is one of the safest invasive procedures in medicine. A landmark UK audit of over 54,890 procedures reported the following:
- Hemorrhage requiring intervention: 0.07%
- Infection: 0.004%
- Persistent pain beyond 14 days: ~2–5%
- Death directly attributable to the procedure: approximately 1 in 50,000
- Needle breakage: rare, but documented — always inspect needles before and after use
Patients on anticoagulants or with platelet counts below 20,000/μL need individualized risk-benefit assessment. Most hematologists will proceed with biopsy at platelet counts above 20,000 and apply firm pressure for 10–15 minutes post-procedure. Holding direct oral anticoagulants for 24–48 hours pre-procedure is common practice, though institutional protocols vary.
What Patients Should Expect: A Quick Walkthrough
You’ll lie face down or on your side. The skin over your lower back is cleaned and draped. Local anesthetic stings briefly, then numbs the area — the key is ensuring the periosteum (the bone’s nerve-rich outer layer) is thoroughly anesthetized. The biopsy needle is advanced with a twisting or drilling motion. You’ll feel deep pressure and possibly a brief, sharp ache when marrow is aspirated. The whole procedure takes 10–20 minutes.
Afterward, a pressure dressing is applied. Most people can resume normal activities within 24 hours. Soreness at the site lasting 3–5 days is completely normal.
Frequently Asked Questions
How painful is a bone marrow biopsy, really?
Most patients rate the pain between 2 and 5 out of 10 with proper local anesthesia. The aspiration moment — when liquid marrow is pulled into the syringe — produces a distinctive deep ache that lasts 5–10 seconds. Operator experience matters enormously: studies show pain scores are significantly lower when the procedure is performed by someone who has done more than 50 biopsies.
Can a bone marrow biopsy be done from sites other than the hip?
Yes. The anterior iliac crest and sternum (aspiration only) are alternatives. In infants, the proximal tibia is commonly used. CT-guided biopsies can target virtually any bone with a suspicious lesion, including vertebral bodies and the femur.
How long does it take to get bone marrow biopsy results?
Aspirate smear and flow cytometry results often return within 24–48 hours. The trephine (core) biopsy requires decalcification, sectioning, and staining, which typically takes 5–7 business days. Molecular/genetic studies may take 2–3 weeks.
Is it safe to take blood thinners before a bone marrow biopsy?
Most centers ask patients to stop warfarin 3–5 days prior and direct oral anticoagulants (like apixaban or rivarelbain) 24–48 hours prior. Aspirin alone is generally not stopped. Always follow your hematologist’s specific instructions — the risk of bleeding must be weighed against the risk of stopping anticoagulation.
Why would a doctor order a repeat bone marrow biopsy?
Common reasons include monitoring treatment response (e.g., after chemotherapy for leukemia), evaluating disease progression, assessing for relapse, restaging lymphoma, or re-evaluating when the first specimen was inadequate. Some treatment protocols mandate biopsies at defined intervals — for example, day-14 and day-28 marrows in AML induction therapy.
Key Takeaways
- The posterior superior iliac spine is the default biopsy site for adults — safe, accessible, and high-yield.
- Aim for a core specimen ≥2 cm at the bedside to meet diagnostic standards after processing shrinkage.
- Powered biopsy devices reduce procedure time and improve specimen quality compared to manual needles.
- Serious complications occur in fewer than 0.1% of cases, making this one of the safest invasive diagnostic procedures.
- Modern bone marrow workup extends far beyond morphology — flow cytometry, cytogenetics, and NGS panels are now routine and often drive treatment decisions.
